Search clinical trials for: CHF6001

Total 13 results

Chiesi Farmaceutici S.p.A.

Completed

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD) | COPD

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

COPD

United Kingdom, Ireland
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Argentina, Austria, Bosnia and Herzegovina, Chile, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Israel, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian Federation and more
Chiesi Farmaceutici S.p.A.

Recruiting

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PILASTER)

Chronic Obstructive Pulmonary Disease

Bulgaria, United States, Albania, Argentina, Australia, Austria, Bosnia and Herzegovina, Chile, China, Czechia, Georgia, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, North Macedonia, Poland, Romania, Russian... and more
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics (CHF6001_POC2)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.
Quintiles, Inc.

Completed

Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

Copd

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Recruiting

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy (TANGO)

Uncontrolled Asthma

Argentina, Bulgaria, Czechia, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Poland, Romania, South Africa, Spain
Chiesi Farmaceutici S.p.A.

Completed

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 (CHF6001Ext)

Chronic Obstructive Pulmonary Disease

United Kingdom
Corthera, Inc.(formerly BAS Medical, Inc.), a member...

Completed

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF)

Heart Failure, Congestive

United States, Israel
Chiesi Farmaceutici S.p.A.

Completed

A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD (PIONEER)

Chronic Obstructive Pulmonary Disease
Chiesi Farmaceutici S.p.A.

Completed

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

Chronic Obstructive Pulmonary Disease

Belgium

Search clinical trials for: CHF6001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations